









市场行情
/
股票
/
nasdaq-fbrx
/

Forte Biosciences Inc

FBRX

28.685USD

-0.645-2.20%

交易中（美东）报价延迟15分钟

359.25M总市值

亏损市盈率 TTM



Forte Biosciences Inc

28.685

-0.645-2.20%

概览公司财务分析

概览

公司

财务

分析

关于 Forte Biosciences Inc 公司

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

Forte Biosciences Inc简介



公司代码FBRX

公司名称Forte Biosciences Inc

上市日期Apr 13, 2017

CEOWagner (Paul A)

员工数量14

证券类型Ordinary Share

年结日Apr 13

公司地址3060 Pegasus Park Drive

城市DALLAS

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编75247

电话13106186994

网址https://www.fortebiorx.com/home/default.aspx

公司代码FBRX

上市日期Apr 13, 2017

CEOWagner (Paul A)

Forte Biosciences Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Paul A. Wagner, Ph.D.

Chairman of the Board, President, Chief Executive Officer

82.09K

+1.42%

Mr. Antony A. Riley

Chief Financial Officer

31.70K

+0.77%

Mr. David W. (Dave) Gryska

Independent Director

5.94K

Mr. Steven Kornfeld

Independent Director

3.96K

Dr. Barbara K. Finck, M.D.

Director, Senior Medical Clinician

Dr. Stephen K. Doberstein, Ph.D.

Independent Director

Mr. Richard G. (Rich) Vincent, CPA

Independent Director

Dr. Scott C. Brun, M.D.

Independent Director

Mr. Shiv Kapoor

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Paul A. Wagner, Ph.D.

Chairman of the Board, President, Chief Executive Officer

82.09K

+1.42%

Mr. Antony A. Riley

Chief Financial Officer

31.70K

+0.77%

Mr. David W. (Dave) Gryska

Independent Director

5.94K

Mr. Steven Kornfeld

Independent Director

3.96K

Dr. Barbara K. Finck, M.D.

Director, Senior Medical Clinician

Dr. Stephen K. Doberstein, Ph.D.

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Fred Alger Management, LLC

13.06%

Federated Hermes Global Investment Management Corp.

13.05%

Janus Henderson Investors

11.21%

OrbiMed Advisors, LLC

9.56%

Tybourne Capital Management (HK) Limited

6.28%

其他

46.84%

持股股东

占比

Fred Alger Management, LLC

13.06%

Federated Hermes Global Investment Management Corp.

13.05%

Janus Henderson Investors

11.21%

OrbiMed Advisors, LLC

9.56%

Tybourne Capital Management (HK) Limited

6.28%

其他

46.84%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

46.88%

Hedge Fund

20.01%

Private Equity

9.56%

Investment Advisor

7.18%

Corporation

3.92%

Individual Investor

1.02%

Research Firm

0.12%

其他

11.31%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

10.85M

55.59%

2025Q3

10.85M

55.60%

+222.21K

2025Q2

10.20M

43.87%

+4.95M

2025Q1

5.29M

79.85%

+32.05K

2024Q4

5.16M

31.17%

+3.22M

2024Q3

789.31K

58.51%

-26.11K

2024Q2

815.46K

58.79%

-11.24K

2024Q1

101

826.69K

59.45%

-38.71K

2023Q4

113

819.35K

60.39%

+5.27K

2023Q3

130

814.23K

49.33%

+164.66K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fred Alger Management, LLC

1.62M

13.02%

+708.04K

+77.75%

Jun 30, 2025

Federated Hermes Global Investment Management Corp.

1.48M

11.89%

+406.41K

+37.90%

Aug 31, 2025

Janus Henderson Investors

1.39M

11.22%

+474.85K

+51.61%

Jun 30, 2025

OrbiMed Advisors, LLC

1.20M

9.63%

+603.87K

+101.82%

Jun 30, 2025

Tybourne Capital Management (HK) Limited

786.65K

6.33%

+166.67K

+26.88%

Jun 30, 2025

The Vanguard Group, Inc.

486.92K

3.92%

+397.97K

+447.40%

Jun 30, 2025

Cable Car Capital LLC

500.00K

4.02%

+280.40K

+127.68%

Jun 30, 2025

Sphera Funds Management Ltd.

495.11K

3.98%

+495.11K

Jun 30, 2025

Nemean Asset Management, LLC

432.28K

3.48%

+432.28K

Nov 22, 2024

Adage Capital Management, L.P.

333.33K

2.68%

+333.33K

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Alger 35 ETF

1.35%

Texas Capital Texas Small Cap Equity Index ETF

0.06%

iShares Micro-Cap ETF

0.01%

Dimensional US Core Equity 1 ETF

iShares Core S&P Total U.S. Stock Market ETF

Fidelity Nasdaq Composite Index ETF

Alger Mid Cap 40 ETF

Avantis US Small Cap Equity ETF

Alger 35 ETF

占比1.35%

Texas Capital Texas Small Cap Equity Index ETF

占比0.06%

iShares Micro-Cap ETF

占比0.01%

Dimensional US Core Equity 1 ETF

占比0%

iShares Core S&P Total U.S. Stock Market ETF

占比0%

Fidelity Nasdaq Composite Index ETF

占比0%

Alger Mid Cap 40 ETF

占比0%

Avantis US Small Cap Equity ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

公告日期

类型

比率

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Aug 22, 2024

Merger

25→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

Jun 15, 2020

Merger

15→1

常见问题

Forte Biosciences Inc的前五大股东是谁？



Forte Biosciences Inc 的前五大股东如下：
Fred Alger Management, LLC持有股份：1.62M，占总股份比例：13.02%。
Federated Hermes Global Investment Management Corp.持有股份：1.48M，占总股份比例：11.89%。
Janus Henderson Investors持有股份：1.39M，占总股份比例：11.22%。
OrbiMed Advisors, LLC持有股份：1.20M，占总股份比例：9.63%。
Tybourne Capital Management (HK) Limited持有股份：786.65K，占总股份比例：6.33%。